-
1Academic Journal
المؤلفون: S. A. Tjulandin, M. B. Stenina, M. A. Frolova, С. А. Тюляндин, М. Б. Стенина, М. А. Фролова
المصدر: Malignant tumours; Принято в печать ; Злокачественные опухоли; Принято в печать ; 2587-6813 ; 2224-5057
مصطلحات موضوعية: генетический тест, chemotherapy, test hormonotherapy, genetic tests, химиотерапия, тестовая гормонотерапия
وصف الملف: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1309/932; Ferreira A.R., Di Meglio A., Pistilli B. et al. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Ann Oncol 2019;30(11):1784-1795. https://doi.org/10.1093/annonc/mdz298; Sparano J.A., Gray R.J., Makower D.F. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379(2):111-121. https://doi.org/10.1056/NEJMoa1804710; Kalinsky K., Barlow W.E., Gralow J.R. et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 2021;385(25):2336-2347. https://doi.org/10.1056/NEJMoa2108873; Kalinsky K., Barlow W.E., Meric-Bernstam F. et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). Cancer Research 2021;81(4_Supplement):GS3-00-GS3-00. https://doi.org/10.1158/1538-7445.SABCS20-GS3-00; Sparano J.A., Gray R.J., Ravdin P.M. et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 2019;380(25):2395-2405. https://doi.org/10.1056/NEJMoa1904819; Fabrice A., Ismaila N., Kimberly H.A. et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO Guideline Update. J Clin Oncol 2022;40(16):1816-1837. https://doi.org/10.1200/JCO.22.00069; Curigliano G., Burstein H.J., Gnant M. et al. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol 2023;34(11):970-986. https://doi.org/10.1016/j.annonc.2023.08.017; Orucevic A., Bell J.L., King M. et al. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data. Breast 2019;46:116-125. https://doi.org/10.1016/j.breast.2019.05.006; Smith I., Robertson J., Kilburn L. et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal patients with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol 2020;21(11):1443-1454. https://doi.org/10.1016/S1470-2045(20)30458-7; Burstein H.J., Curigliano G., Thürlimann B. et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 2021;32(10):1216-1235. https://doi.org/10.1016/j.annonc.2021.06.023; Francis P.A., Pagani O., Fleming G.F. et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018;379(2):122-137. https://doi.org/10.1056/NEJMoa1803164; Pagani O., Walley B.A., Fleming G.F. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol 2023;41(7):1376-1382. https://doi.org/10.1200/JCO.22.01064; Regan M.M., Francis P.A., Pagani O. et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT trials. J Clin Oncol 2016;34(19):2221-2231. https://doi.org/10.1200/JCO.2015.64.3171; https://www.malignanttumors.org/jour/article/view/1309